Treatment time to the end of thoracic radiotherapy has more predictive power for survival than radiation dose intensity in patients with limited‑stage small‑cell lung cancer receiving concurrent chemoradiation of more than 45 Gy-Reference-Cited by-同舟云学术

Treatment time to the end of thoracic radiotherapy has more predictive power for survival than radiation dose intensity in patients with limited‑stage small‑cell lung cancer receiving concurrent chemoradiation of more than 45 Gy

Published:2019-11-18 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Jeong Jae‑Uk¹,Jeon Wan²,Ahn Sung‑Ja¹,Kim Young‑Chul³,Oh In‑Jae³,Park Chul‑Kyu³,Yoon Mee¹,Song Ju‑Young¹,Nam Taek‑Keun¹,Chung Woong‑Ki¹

Affiliation:

1. Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun‑gun, Jeollanam‑do 58128, Republic of Korea

2. Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Gijang‑gun, Busan 46033, Republic of Korea

3. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun‑gun, Jeollanam‑do 58128, Republic of Korea

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No survival benefit with early incorporation of thoracic radiotherapy using daily fractionation in patients with limited-stage small cell lung cancer undergoing chemoradiotherapy in the modern era: A systematic review and meta-analysis;Radiotherapy and Oncology;2023-07

2. Survival benefit of prophylactic cranial irradiation in limited-stage small-cell lung cancer in modern magnetic resonance imaging staging: a systematic review and meta-analysis;Acta Oncologica;2023-03-04

3. Sequential Hypofractionated versus Concurrent Twice-Daily Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis;Cancers;2022-08-13

4. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2022-01-28